-
Lifestyle changes plus red yeast rice and fish oil resulted in similar beneficial effects on LDL cholesterol as moderate-dose statin therapy in patients meeting criteria for drug therapy for high LDL cholesterol.
-
Optimizing medical and lifestyle change therapy rather than performing PCI is appropriate as the initial management strategy for most patients with known CAD who do not have unstable or disabling symptoms.
-
-
A randomized controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Using blood pressure, BUN, serum sodium, and presence of peripheral arterial disease as predictors of mortality in heart failure patients, 67% who had 3 or more factors died within 6 months and would qualify for the Medicare hospice benefit.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
The statistics are not new news: "Only about 7% of sites enroll what they say they will enroll," said William Flohrs, PharmD, Associate Clinical Research Consultant, Eli Lilly and Company, Indianapolis, IN.1 "From 1997 to 2003, the studies completed on time decreased from 18% to 6%."
-
Ethicists and others continue to find it troubling that payments to research participants are part of the recruitment process.
-
Determining the ability of patients with Alzheimer's disease to give consent for participation in research can present challenges to researchers and IRBs.
-
It could be argued that successful clinical trials depend on a variety of factors. But perhaps the glue that holds it all together is the study coordinator.
